FDA’s new draft guidance, “Addressing Misinformation About Medical Devices and Prescription Drugs—Questions and Answers,” communicates guidelines for when and how companies can address false or misleading information on the internet about their FDA-approved medical products. It also provides interesting insights into FDA’s thinking on social media and influencer communications.

Join King & Spalding to explore the following questions: 

• What are the key differences between the draft 2014 “Correcting Misinformation” and the revised 2024 “Addressing Misinformation” guidances, and what are the implications for companies? 
• What insights does the 2024 guidance offer for social media, and what are the potential implications for promotional communications? 
• How might the revised guidance impact how companies view and engage with influencer content? 
• What are other important considerations when deciding whether and how to correct online misinformation? 

We look forward to an engaging discussion of these questions and more.